BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 09, 2004
 |  BioCentury  |  Strategy

Vertex's P&L epiphany

Looking out the next few years, Vertex Pharmaceuticals Inc. saw that its plan to reach profitability was going to run headlong into a large ramp-up in development expenses related to its 2000 kinase deal with Novartis AG. Following last week's restructuring of the deal, VRTX believes it may have nipped this impending collision in the bud.

Under the original deal, VRTX had responsibility for early clinical development through biochemical proof-of-concept in humans, defined as late Phase I or early Phase II testing (see BioCentury,...

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >